There is a category of risk most organisations are not measuring, yet it is quietly eroding performance, increasing cost, and undermining leadership continuity. It does not sit on a balance sheet, nor does it trigger immediate incident reports. But it is pervasive, predictable, and, crucially, preventable.
This is the risk posed by non-communicable chronic diseases (NCDs).
For executives, HR leaders, and risk managers, the issue is not simply one of employee wellbeing—it is one of operational resilience, financial exposure, and long-term enterprise value.
Silent Risk Is Still Risk
NCDs—hypertension, diabetes, cardiovascular disease, and chronic kidney disease—are often asymptomatic in their early stages. Individuals can remain high-functioning while underlying pathology progresses unchecked. By the time symptoms present, intervention is more complex, more costly, and less effective.
This is why they are frequently referred to as “silent killers” in the clinical literature: they advance without warning, but their consequences—heart attack, stroke, organ failure—are abrupt and disruptive.]
In the UK, the scale is material. More than one-third of working-age adults report at least one long-term condition, with prevalence rising significantly in the 35–44 age group—precisely the cohort from which leadership pipelines are drawn. Layer onto that the realities of executive life—chronic stress, long sedentary hours, inconsistent nutrition—and the risk profile becomes markedly elevated.
The implication is clear: many organisations are unknowingly carrying latent health risk within their most critical roles.
The Economic Burden: Hidden but Material
From a macroeconomic perspective, the impact of chronic disease is already well established. NCDs account for approximately 70% of health and social care spending in the UK. Food-related chronic disease alone is estimated to cost £268 billion annually, including £116 billion in lost productivity.
Diabetes costs the NHS over £10 billion per year, while broader analyses suggest chronic disease removes hundreds of billions from advanced economies through a combination of absenteeism, presenteeism, and premature workforce exit.
At the organisational level, these figures translate into very real operational consequences:
- Absenteeism: 141 million working days were lost in the UK in 2018 due to sickness.
- Presenteeism: Employees remain at work but operate below capacity—often the larger, less visible cost.
- Leadership disruption: Sudden health events among senior leaders create strategic discontinuity and succession risk.
- Insurance and healthcare costs: Rising claims and premiums linked to unmanaged chronic conditions.
Globally, the trajectory is even more concerning. NCDs are projected to cost the world economy $47 trillion by 2030. For organisations reliant on high-value decision-makers, the concentration of risk is disproportionately high.
Monitoring as a Strategic Control, Not a Perk
The evidence in favour of proactive monitoring is both robust and consistent.
Programmes such as the NHS Health Check have demonstrated measurable impact: earlier detection of hypertension and high cholesterol, increased diagnosis rates within two years, and reductions in long-term multi-morbidity. Longitudinal data also shows lower mortality and reduced incidence of cardiovascular events among participants over time.
For executives, the case is even stronger.
Targeted health assessments—combining blood biomarkers, cardiovascular screening, and stress evaluation—enable early identification of risk factors before they translate into acute events. This is not about reactive healthcare; it is about risk mitigation.
From a commercial standpoint, the benefits are straightforward:
- Reduced unplanned absence through early intervention
- Improved cognitive and physical performance at senior levels
- Lower long-term healthcare costs driven by prevention rather than treatment
- Enhanced decision-making continuity across critical roles
There is also growing evidence that structured workplace health programmes reduce overall employer healthcare expenditure and improve productivity outcomes.
Why This Matters for C-Suite, HR, and Risk Leaders
For the C-suite, this is a governance issue. Boards routinely assess financial, cyber, and operational risks, yet health risk—particularly among key executives—remains under-addressed.
For HR, it is a talent and retention lever. In competitive markets, organisations that demonstrate a proactive commitment to leadership health differentiate themselves meaningfully.
For risk managers, it is a classic case of unmanaged exposure: high impact, high probability, and relatively low cost of mitigation.
Embedding regular health monitoring into organisational practice delivers multiple strategic advantages:
- Protects critical talent and leadership continuity
- Reduces systemic strain on healthcare pathways through early detection
- Strengthens employer brand and executive value proposition
- Aligns with preventative health strategies advocated across public health policy
In short, it shifts the organisation from reactive to preventative risk management.
From Insight to Action
Addressing silent risk does not require wholesale transformation—just deliberate prioritisation.
Practical steps include:
- Institutionalise executive screening: Bi-annual or annual assessments, aligned with NHS Health Check frameworks or equivalent private provision
- Measure outcomes rigorously: Track absenteeism, health claims, and productivity indicators to quantify return on investment
- Integrate with broader wellbeing strategy: Stress management, nutrition, and lifestyle interventions amplify the impact of monitoring
- Position as risk management, not benefit: This reframing is critical for sustained executive buy-in
Final Thought
Most organisations invest heavily in identifying visible risks. The more sophisticated ones recognise that the most damaging risks are often the least visible.
Non-communicable chronic diseases fall squarely into that category.
They are predictable. They are measurable. And, with the right interventions, they are largely preventable.
The question is not whether this risk exists within your organisation. It almost certainly does.
The question is whether you are choosing to manage it.